These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 29587321)

  • 1. [Immunotherapy with checkpoint inhibitors in local advanced and metastatic urothelial carcinoma].
    Miller K; Gschwend JE; Merseburger A; Retz M; Stenzl A
    Aktuelle Urol; 2018 Apr; 49(2):142-156. PubMed ID: 29587321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update of systemic immunotherapy for advanced urothelial carcinoma.
    Gartrell BA; He T; Sharma J; Sonpavde G
    Urol Oncol; 2017 Dec; 35(12):678-686. PubMed ID: 29079131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
    Tripathi A; Plimack ER
    Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Renaissance of immuno-oncology for urological tumors : Current status].
    Grimm MO; Winkler Y; Fetter I; Oppel-Heuchel H
    Urologe A; 2016 May; 55(5):621-6. PubMed ID: 27119960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for the Treatment of Urothelial Carcinoma.
    Donin NM; Lenis AT; Holden S; Drakaki A; Pantuck A; Belldegrun A; Chamie K
    J Urol; 2017 Jan; 197(1):14-22. PubMed ID: 27460757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis.
    Di Nunno V; De Luca E; Buttigliero C; Tucci M; Vignani F; Gatto L; Zichi C; Ardizzoni A; Di Maio M; Massari F
    Crit Rev Oncol Hematol; 2018 Sep; 129():124-132. PubMed ID: 30097230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarker challenges for immune checkpoint inhibitors in urothelial carcinoma.
    Powles T; Morrison L
    Nat Rev Urol; 2018 Oct; 15(10):585-587. PubMed ID: 30030491
    [No Abstract]   [Full Text] [Related]  

  • 8. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urothelial cancer in 2017: Changes in expectations for metastatic urothelial carcinoma.
    Bellmunt J; Nadal R
    Nat Rev Clin Oncol; 2018 Feb; 15(2):73-74. PubMed ID: 29203837
    [No Abstract]   [Full Text] [Related]  

  • 10. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
    Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
    World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunooncology in Urologic Cancers: Current Status].
    Grimm MO
    Aktuelle Urol; 2016 Sep; 47(5):374-7. PubMed ID: 27680188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update.
    Nagai H; Muto M
    Int J Clin Oncol; 2018 Jun; 23(3):410-420. PubMed ID: 29516216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surrogate end points for overall survival in trials of PD-(L)1 inhibitors for urinary cancers: a systematic review.
    Abdel-Rahman O
    Immunotherapy; 2018 Feb; 10(2):139-148. PubMed ID: 29260622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in medical therapy for metastatic urothelial cancer.
    Yuasa T; Urakami S; Yonese J
    Int J Clin Oncol; 2018 Aug; 23(4):599-607. PubMed ID: 29556919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting advanced urothelial carcinoma-developing strategies.
    Alhalabi O; Rafei H; Shah A; Siefker-Radtke A; Campbell M; Gao J
    Curr Opin Oncol; 2019 May; 31(3):207-215. PubMed ID: 30844889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute Flare of Bullous Pemphigus With Pembrolizumab Used for Treatment of Metastatic Urothelial Cancer.
    Garje R; Chau JJ; Chung J; Wanat K; Zakharia Y
    J Immunother; 2018 Jan; 41(1):42-44. PubMed ID: 29111983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Checkpoint inhibition: new treatment options in urologic cancer.
    De Maeseneer DJ; Delafontaine B; Rottey S
    Acta Clin Belg; 2017 Feb; 72(1):24-28. PubMed ID: 28151378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019.
    Grimm MO; Bex A; De Santis M; Ljungberg B; Catto JWF; Rouprêt M; Hussain SA; Bellmunt J; Powles T; Wirth M; Van Poppel H
    Eur Urol; 2019 Sep; 76(3):368-380. PubMed ID: 31235192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caring for Patients Treated With Checkpoint Inhibitors for the Treatment of Metastatic Merkel Cell Carcinoma.
    Rubin KM; Hoffner B; Bullock AC
    Semin Oncol Nurs; 2019 Oct; 35(5):150924. PubMed ID: 31514991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.
    Katz H; Wassie E; Alsharedi M
    Med Oncol; 2017 Sep; 34(10):170. PubMed ID: 28864844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.